APOA1 and cardiovascular disorder: Individuals with very high HDL‐C may be at increased risk of developing cardiovascular disease,2 and therapies to raise circulating HDL‐C have not shown significant improvements in cardiovascular health.3 Additionally, individuals carrying certain mutations of the main HDL protein, apolipoprotein A‐I (apoA‐I), including the Milano (R173C)4 and Zaragoza (L144R)5 variants, have a low predisposition to cardiovascular disease, despite having naturally low levels of circulating HDL‐C.